Advanced Enzyme Technologies（ADVENZYMES）株式概要
アドバンスド・エンザイム・テクノロジーズ・リミテッドは、その子会社とともに、インド、ヨーロッパ、米国、アジア、そして国際的に酵素とプロバイオティクスの研究、開発、製造、販売に従事している。 詳細
報酬
リスク分析
リスクチェックの結果、ADVENZYMES 、リスクは検出されなかった。
ADVENZYMES Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Advanced Enzyme Technologies Limited 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | ₹298.30 |
| 52週高値 | ₹419.00 |
| 52週安値 | ₹251.95 |
| ベータ | 0.69 |
| 1ヶ月の変化 | -9.57% |
| 3ヶ月変化 | -18.93% |
| 1年変化 | -0.50% |
| 3年間の変化 | -10.55% |
| 5年間の変化 | -19.40% |
| IPOからの変化 | 8.46% |
最新ニュース
Recent updates
分析記事 • Jul 15
Impressive Earnings May Not Tell The Whole Story For Advanced Enzyme Technologies (NSE:ADVENZYMES)
Advanced Enzyme Technologies Limited's ( NSE:ADVENZYMES ) robust earnings report didn't manage to move the market for...分析記事 • Jun 30
If EPS Growth Is Important To You, Advanced Enzyme Technologies (NSE:ADVENZYMES) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
ナラティブ更新 • Jun 18
ADVENZYMES: Stable Case Balances Model Assumptions And Upcoming Dividend Decisions
Analysts have kept their ₹370 price target on Advanced Enzyme Technologies unchanged, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E that, in their view, broadly offset each other in the valuation model. Analyst Commentary Recent commentary on Advanced Enzyme Technologies highlights a mix of optimism about the company’s positioning and caution around execution and valuation assumptions, which feeds into how analysts are thinking about the ₹370 target.ナラティブ更新 • Jun 01
ADVENZYMES: Steady Cash Assumptions And Upcoming Board Decisions Will Shape Returns
Narrative update on Advanced Enzyme Technologies The analyst price target for Advanced Enzyme Technologies is held steady at ₹370, as analysts point to only very small adjustments in assumptions for discount rate, revenue growth, profit margin and forward P/E after reviewing recent research on comparable companies. Analyst Commentary Recent Street research on other mid-cap service companies has given analysts a reference point as they revisit models for Advanced Enzyme Technologies, even though those reports focus on a different stock.ナラティブ更新 • May 12
ADVENZYMES: Stable Margins And Refined Assumptions Will Guide Future Returns
Analysts kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, citing modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions rather than any change in their core outlook. Analyst Commentary Analysts keeping fair value at ₹370 are focusing on how well Advanced Enzyme Technologies can execute on its current plan rather than changing their fundamental view of the stock.ナラティブ更新 • Apr 19
ADVENZYMES: Steady Risk And Margins Will Support Future Upside
Analysts have kept their fair value estimate for Advanced Enzyme Technologies steady at ₹370. They cited updated assumptions around the discount rate, growth, margins and future P/E that reflect fine tuning of their models rather than a change in overall conviction.ナラティブ更新 • Apr 05
ADVENZYMES: Steady Assumptions And Risk Profile Will Support Future Upside
Analysts have kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, with only small adjustments to the discount rate, growth, margin and future P/E assumptions informing this unchanged price target. Analyst Commentary Bullish Takeaways Bullish analysts see support for the ₹370 fair value estimate from the decision to keep key model assumptions, such as growth and margins, broadly consistent rather than revising them sharply.ナラティブ更新 • Mar 21
ADVENZYMES: Refined Risk Assumptions And Stable Outlook Will Support Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370, making small changes to assumptions such as a slightly lower discount rate and marginally adjusted long-term growth and P/E inputs after revisiting their models. Analyst Commentary Bullish Takeaways Bullish analysts see the reaffirmed fair value of ₹370 as supported by refreshed assumptions, suggesting that the refined discount rate and long term inputs still back the existing valuation framework for Advanced Enzyme Technologies.ナラティブ更新 • Mar 06
ADVENZYMES: Free Cash Flow Momentum And Cleaner Portfolio Will Drive Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370.0 per share, while slightly adjusting assumptions on discount rate, growth, margins and future P/E to reflect updated free cash flow trends and a cleaner portfolio. They expect these factors to support improvement in the second half.ナラティブ更新 • Feb 20
ADVENZYMES: Stable Assumptions And Future P/E Reset Will Drive Upside
Analysts have kept their price target for Advanced Enzyme Technologies steady at ₹370, citing largely unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E in their updated models. What's in the News A board meeting is scheduled on January 31, 2026 to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).ナラティブ更新 • Feb 05
ADVENZYMES: Future P/E Reset Will Signal Upside Potential For Shares
Analysts have trimmed their fair value estimate for Advanced Enzyme Technologies from ₹440 to ₹370, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower future P/E multiple. What's in the News Board meeting scheduled for January 31, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).分析記事 • Jan 31
Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Share Price Not Quite Adding Up
There wouldn't be many who think Advanced Enzyme Technologies Limited's ( NSE:ADVENZYMES ) price-to-earnings (or "P/E...新しいナラティブ • Aug 17
Preventive Health And Green Chemistry Will Expand Future Markets
Key Takeaways Expansion into health, wellness, and sustainable enzymatic solutions, along with new B2C initiatives, positions for growth and improved margins as consumer demand rises. International diversification, R&D investment, and increased capacity utilization support long-term product differentiation, earnings stability, and operating leverage.分析記事 • Aug 04
Here's What's Concerning About Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...分析記事 • Jun 27
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Dividend Will Be ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...分析記事 • Jun 12
Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Due To Pay A Dividend Of ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...分析記事 • Mar 25
Is Advanced Enzyme Technologies (NSE:ADVENZYMES) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Aug 20
After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar
Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) shareholders have had their patience rewarded with a 26% share...分析記事 • Jul 19
We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now
Key Insights Advanced Enzyme Technologies' Annual General Meeting to take place on 25th of July Salary of ₹6.69m is...分析記事 • Jul 13
Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.00...分析記事 • Apr 08
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
What are the early trends we should look for to identify a stock that could multiply in value over the long term...分析記事 • Sep 23
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...株主還元
| ADVENZYMES | IN Chemicals | IN 市場 | |
|---|---|---|---|
| 7D | -7.5% | 0.6% | 0.1% |
| 1Y | -0.5% | 1.5% | 5.2% |
業界別リターン: ADVENZYMES過去 1 年間で1.5 % の収益を上げたIndian Chemicals業界を下回りました。
リターン対市場: ADVENZYMESは、過去 1 年間で5.2 % のリターンを上げたIndian市場を下回りました。
価格変動
| ADVENZYMES volatility | |
|---|---|
| ADVENZYMES Average Weekly Movement | 5.7% |
| Chemicals Industry Average Movement | 6.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.7% |
安定した株価: ADVENZYMES 、 Indian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: ADVENZYMESの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1957 | 409 | Mukund Kabra | www.advancedenzymes.com |
アドバンスド・エンザイム・テクノロジーズ社は、その子会社とともに、インド、欧州、米国、アジア、および国際的な酵素およびプロバイオティクスの研究、開発、製造、販売に従事している。酵素とプロバイオティクスをベースとした栄養補助食品を、ヒトの健康管理、動物栄養、果物・野菜加工、製パン、醸造・製麦、でんぷん・穀物加工、たんぱく質改質、酵母加工、乳製品・チーズ加工、油脂加工、特殊用途、バイオ燃料、バイオ触媒向けに提供している。また、繊維、皮革、紙パルプ加工用の非食品加工用酵素や、洗剤、洗浄助剤も提供している。以前はアドバンスト・バイオケミカルズ社として知られていたが、2005年にアドバンスト・エンザイム・テクノロジーズ社に社名変更。アドバンスト・エンザイム・テクノロジーズ社は 1957 年に設立され、インドのテーンに本拠を置く。
Advanced Enzyme Technologies Limited 基礎のまとめ
| ADVENZYMES 基礎統計学 | |
|---|---|
| 時価総額 | ₹32.98b |
| 収益（TTM） | ₹1.66b |
| 売上高(TTM) | ₹7.54b |
20.1x
PER（株価収益率4.4x
P/SレシオADVENZYMES は割高か？
公正価値と評価分析を参照収益と収入
| ADVENZYMES 損益計算書（TTM） | |
|---|---|
| 収益 | ₹7.54b |
| 売上原価 | ₹2.07b |
| 売上総利益 | ₹5.47b |
| その他の費用 | ₹3.81b |
| 収益 | ₹1.66b |
直近の収益報告
Jun 30, 2026
次回決算日
Aug 12, 2026
| 一株当たり利益（EPS） | 14.81 |
| グロス・マージン | 72.54% |
| 純利益率 | 22.01% |
| 有利子負債／自己資本比率 | 1.2% |
ADVENZYMES の長期的なパフォーマンスは？
過去の実績と比較を見る| Advanced Enzyme Technologies 配当日 | |
|---|---|
| 配当落ち日 | Jul 24 2026 |
| 配当支払日 | Aug 30 2026 |
| 配当落ちまでの日数 | 19 days |
| 配当支払日までの日数 | 18 days |
ADVENZYMES 配当は確実ですか？
ADVENZYMES 配当履歴とベンチマークを見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/11 14:46 |
| 終値 | 2026/08/11 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2026/03/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Advanced Enzyme Technologies Limited 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4
| アナリスト | 機関 |
|---|---|
| Nandan Chakraborty | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| null null | DBS Bank Ltd |